351 related articles for article (PubMed ID: 15709885)
21. There have been inadequate warnings that erectile dysfunction drugs can cause blindness.
Wolfe SM
MedGenMed; 2005 Dec; 7(4):61. PubMed ID: 16614683
[No Abstract] [Full Text] [Related]
22. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
[TBL] [Abstract][Full Text] [Related]
23. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
[No Abstract] [Full Text] [Related]
24. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
Eardley I; Mirone V; Montorsi F; Ralph D; Kell P; Warner MR; Zhao Y; Beardsworth A
BJU Int; 2005 Dec; 96(9):1323-32. PubMed ID: 16287454
[TBL] [Abstract][Full Text] [Related]
25. Erectile dysfunction: oral pharmacotherapy options.
Vitezic D; Pelcic JM
Int J Clin Pharmacol Ther; 2002 Sep; 40(9):393-403. PubMed ID: 12358156
[TBL] [Abstract][Full Text] [Related]
26. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
Scranton RE; Goldstein I; Stecher VJ
J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
[TBL] [Abstract][Full Text] [Related]
27. Cardiovascular parameter changes in patients with erectile dysfunction using pde-5 inhibitors: a study with sildenafil and vardenafil.
Pomara G; Morelli G; Pomara S; Taddei S; Ghiadoni L; Dinelli N; Travaglini F; Dicuio M; Mondaini N; Salvetti A; Selli C
J Androl; 2004; 25(4):625-9. PubMed ID: 15223851
[TBL] [Abstract][Full Text] [Related]
28. Erectile dysfunction.
Katz A; Katz A
CMAJ; 2010 Mar; 182(4):381-2. PubMed ID: 20142374
[No Abstract] [Full Text] [Related]
29. Phosphodiesterase 5 inhibitors for erectile dysfunction.
Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
[TBL] [Abstract][Full Text] [Related]
30. Towards optimal ED management: educational forum - II.
Brock G
Can J Urol; 2001 Dec; 8(6):1419-20. PubMed ID: 11799971
[No Abstract] [Full Text] [Related]
31. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
Kamenov ZA
J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
[TBL] [Abstract][Full Text] [Related]
32. Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.
Harv Health Lett; 2004 Jan; 29(3):3. PubMed ID: 14734283
[No Abstract] [Full Text] [Related]
33. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
34. The phosphodiesterase inhibitor 'war'.
Wyllie MG
BJU Int; 2003 Apr; 91(6):573-4. PubMed ID: 12656917
[No Abstract] [Full Text] [Related]
35. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
Herlemann A; Gratzke C; Andersson KE; Sievert KD
Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
[TBL] [Abstract][Full Text] [Related]
36. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
37. Detection and validated quantification of the phosphodiesterase type 5 inhibitors sildenafil, vardenafil, tadalafil, and 2 of their metabolites in human blood plasma by LC-MS/MS--application to forensic and therapeutic drug monitoring cases.
Rust KY; Wilkens H; Kaiser R; Bregel D; Wilske J; Kraemer T
Ther Drug Monit; 2012 Dec; 34(6):729-35. PubMed ID: 23128911
[TBL] [Abstract][Full Text] [Related]
38. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Vardi M; Nini A
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002187. PubMed ID: 17253475
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications.
Agarwal P; Sander GE; Giles TD
Am J Geriatr Cardiol; 2004; 13(6):332-5. PubMed ID: 15538074
[No Abstract] [Full Text] [Related]
40. A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.
Govier F; Potempa AJ; Kaufman J; Denne J; Kovalenko P; Ahuja S
Clin Ther; 2003 Nov; 25(11):2709-23. PubMed ID: 14693299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]